Therefore, studies on the use of PARP inhibitors in combination with other chemotherapy have been under active investigation in various cancer types but has faced challenges due to hematologic or gastrointestinal toxicities associated with the inhibition of other PARP family enzyme such as PARP5 or PARP6 is related with these [14]. This evidence concerns the gene PARP1 and cancer.